TP53 and colorectal carcinoma: Overall, we found that the evaluated autoantigens target of autoantibodies -except p53- could discriminate with statistical significance (p<0.05) among the pathological individuals (CRC patients and premalignant individuals) and all control groups, as well as all controls vs CRC patients (Figure 3A, B).